nonalcoholic%20fatty%20liver%20disease
NONALCOHOLIC FATTY LIVER DISEASE

Nonalcoholic fatty liver disease is having excessive hepatic fat (in the form of triglycerides) accumulation not due to excessive alcohol consumption or other secondary causes.

It is considered as a hepatic manifestation of metabolic syndrome.

Progression of nonalcoholic fatty liver disease is variable.

Surgical Intervention

Bariatric Surgery
  • Alternative therapy in patients unresponsive to lifestyle changes and pharmacological therapy to reduce weight and metabolic complications as it has long-term stable results
  • It was shown in the surrogate markers that bariatric surgery is effective on NAFLD-associated liver injury and there is also initial evidence for improved necroinflammation and fibrosis
  • It is advised that surgery should be done before the patient becomes cirrhotic
Liver Transplantation
  • Accepted procedure in NASH patients with end-stage liver disease
  • It was found that overall survival after transplantation is approximately identical with patients who received liver transplants for hepatic failure caused by other liver diseases
  • Comorbid conditions limit eligibility for transplantation
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 3 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

6 days ago
Treatment with tradipitant in patients with idiopathic or diabetic gastroparesis produces meaningful improvements in nausea and vomiting, according to the results of a phase II trial.